Skip to main content
. Author manuscript; available in PMC: 2009 Jun 1.
Published in final edited form as: Mol Genet Metab. 2008 Mar 17;94(2):190–203. doi: 10.1016/j.ymgme.2008.01.013

Table 2.

Recovery of GCase Activity after CBE Injections

Genotype Injections/ Brain Liver Lung
Harvest 1 nmoles/h/mg 2 %3 nmoles/h/mg % nmoles/h/mg %
WT-CBE
(n=5)		 3/3 hr 1.30(±0.35), 4.5 0.79(±0.13), 2.8 0.99 (±0.09), 2.3
WT-CBE
(n=10)		 6/24 hr 2.95 (±0.25), 10.2 5.82 (±0.52), 20.3 6.52 (±1.10), 15.1
9V-CBE
(n=5)		 3/3 hr 0.63 (±0.04), 2.2 0.17 (±0.04), 0.6 0.14 (±0.06), 0.3
9V-CBE
(n=7)		 6/24 hr 2.09 (±0.16), 7.2 1.21 (±0.20), 4.2 1.48 (±0.10), 3.4
9H-CBE
(n=5)		 3/3 hr 1.44 (±0.07), 5.0 0.39 (±0.05), 1.4 0.84 (±0.0.10), 1.9
9H-CBE
(n=8)		 6/24 hr 3.78 (±0.22), 13.1 2.73 (±0.15), 9.5 2.70 (±0.0.22), 6.3
9V/9V
(n=9)		 No-CBE 5.56 (±0.52), 19.1 1.86 (±0.25), 6.5 1.67 (±0.24), 3.9
1

Injections=number of 100 mg/kg/day single dose injections; Harvest=time (hours) of tissue harvest following the injection of CBE.

2

GCase activity (±SEM).

3

% of non-CBE treated WT mouse GCase activity (see in Table 1).